

Corporate Overview

July 2024



Powering genetic medicines through tissue-specific delivery


 Novel SORT LNP platform engineered for higher potency delivery Precision extrahepatic delivery with tunable tissue specificity and cell tropism Multiple routes of administration 	Clinical Programs	 First-in-class inhaled mRNA treatment for primary ciliary dyskinesia (PCD) Best-in-class inhaled mRNA treatment for cystic fibrosis (CF)
	Research	 Precision extrahepatic delivery with tunable tissue specificity and cell tropism

- Program deals for PCD and CF
- **Discovery research collaborations** across lung, liver, CNS
- Tech synergy delivering diverse genetic cargoes to demonstrate tissue- and cell-selective genome engineering



Partnering

Experienced team and strong investor syndicate






\$370M Raised

Diverse clinical and research pipeline with first and best-in-class opportunities

Respiratory Indications	Candidate	Modality	Target	Delivery	Discovery	Preclinical	Phase 1/2
Primary Ciliary	RCT1100	mRNA	DNAI1	Inhaled			
Dyskinesia		mRNA	CCDC39 /40	Inhaled			
(PCD)		mRNA	PCD gene 3	Inhaled			
Cystic Fibrosis	RCT2100	mRNA	CFTR	Inhaled			
(CF)		Gene correction	CFTR	Inhaled			
Other lung indications		Multiple	Undisclosed	Inhaled IV			
		mRNA	Undisclosed	Inhaled IV			
Other		Multiple	Undisclosed	Inhaled IV			
Liver Indications		1			-		
Various		Multiple	Undisclosed	IV		AskBio	
		Multiple	Undisclosed	IV			
CNS Indications						_	
Various	7	Multiple	Undisclosed	Intrathecal			

ReCode

Significant opportunity with near-term milestones and cash through end of Q3 '25





Abbreviations: BLA (application for accelerated marketing approval), DC (development candidate), IA (interim analysis to trigger start of confirmatory study for accelerated approval), FA (full analysis), GC (gene correction), MAD (multiple ascending dose), NHP (non-human primate), POA (proof of activity, e.g., convincing trend of clinically meaningful effect), POM (proof of mechanism, e.g., editing of human bronchial epithelial cells), SAD (single ascending dose)

2024 Progress to Date

CF and PCD Program updates



Filed INDs and ex-US regulatory filings for CF and PCD



Nearly 100 Healthy volunteers dosed across both studies



PCD HV study completed, Ph1 SAD in patients initiated




CF HV study nearing completion, dose range established for Ph1b MAD patient study

Platform/Partnering updates



First demonstration of durable and persistent editing of lung epithelial cells, published in Science

Demonstrated high levels of hepatic and extrahepatic delivery following IV SORT administration



Financing/Runway update



Completed \$75M Series B extension; Cash runway through Q3 '25

Cystic Fibrosis (CF): RCT2100





Two different treatment approaches to address CF patient needs


	CFTR mRNA replacement	CFTR gene correction		
Cargo	mRNA optimized for stability, translation efficiency and reduced immune activation	All-in-one HDR- independent gene correction machinery		
Administration	Inhaled SORT LNP	Inhaled SORT LNP		
Target	Airway epithelial cells (secretory and ionocytes)	Airway basal (stem) cells		
Population	~13K patients not eligible for or unable to tolerate CFTR modulators	~100K All adults with CF		



Focus on the 10%+ of CF patients with no treatment

For ~130,000 patients worldwide, the following classes of mutations are eligible for CFTR modulators:





>\$1B commercial opportunity

*31 years life expectancy



Cystic Fibrosis Foundation

*Examples of class I – V mutations


*2022 CFF Patient Registry Annual Report, Hill et. al. Journal of Cystic Fibrosis 21 (2022)

production

G542X, R553X,

W1282X*

RCT2100 exceeds potency F508del/F508del CF HBEs





RCT2100 shows significant potency and efficacy in patient-derived fully differentiated CF HBEs in the presence of mucus via apical delivery



PET/CT CF Ferret Tracheal Mucociliary Clearance Assay


- Instill 50 μ L of Ga⁶⁸ macroaggregated albumin at carina
- Image movement for 15 minutes








RCT2100 LNP Efficiently Delivers to Tracheal Epithelium of CF Ferrets in the Presence of Mucus (Single Intratracheal Administration)





Grade 1 disease severity


- Dehydrated mucus
- MCC defect
- No mucus plugs or sig. lung infections





RCT2100


High levels of CFTR dependent MCC recovery observed within 24-hours after administration






RCT2100

CF Phase 1 SAD Healthy Volunteer Study (Ongoing)





CF Phase 1 MAD Patient Study will test three doses






Primary Ciliary Dyskinesia (PCD)






PCD is an orphan respiratory disease with no approved treatment

PCD is a rare disease caused by mutations in genes resulting in dysfunctional cilia, leading to deficient mucociliary clearance (MCC), chronic respiratory infections and loss of lung function



PCD has a high burden disease for patients

Primary Ciliary Dyskinesia (PCD) is a genetic disorder that affects the lungs primarily, but the cilia lining the upper and lower respiratory tract, along with other tracts in the body.



"People with PCD experience a diminished quality of life."

Pediatric Pulmonologist at PCD Clinic

- If left untreated, children with PCD can have lung damage early in life.
- Adults may go undiagnosed while their disease gets progressively worse.



Strong physician and patient enthusiasm for RCT1100

First disease modifying treatment for PCD Patients

"There's nothing out there that offers a therapy that addresses the mutation and gets to disease modification. I think [RCT1100] would galvanize the community to increase awareness and promote early diagnosis as well."

—Pulmonologist, Stanford University

Favorable Dosing and Administration


Less than 10 mins to administer with PARI eflow nebulizer

"Patients would be very excited to see those administration times. Many patients are on over an hour of treatment regimens per day and would happily trade that for 30-minutes a week for treatment that increases lung function. It's a no-brainer for them." —Pediatric Pulmonologist, Naval Medical Center of San Diego





PCD is >\$1B franchise opportunity with no competition






RCT1100 is an inhaled mRNA therapeutic targeting DNAI1 mutation


PCD

ReCode

is caused by pathogenic mutations in DNAI1, a gene that encodes a protein



Restoration of DNAI1 protein and ciliary activity at 0.9 ug/cm2 (predicted ~3 mg nebulized dose) following repeated dosing with nebulized RCT1100 in patient hNEs






RCT1100

NHP data demonstrate dose-dependent increase in expression of DNAI1 protein in target cells and rapid clearance


Protein level derived from mRNA delivered via nebulization is dose-dependent

Vehicle Control



Low dose (3x/week)


SORT LNP lipids are cleared rapidly from the NHP lung



Clear signal accumulation and high levels of protein expression are detected in the airway epithelial cells and cilia of NHPs after 6-week repeat-dose studies even at a low-dose (0.14 mg/kg; images at 24 hours post-dose) Ionizable lipid, DMG-PEG, and SORT lipid levels at or below the limit of quantification at 48-hours following single-dose inhalation administration at low dose (0.11 mg/kg) or high dose (0.34 mg/kg)



RCT1100: Phase 1b clinical functional biomarker study to confirm proof-of-activity




Immunofluorescence (IF)

showing protein expression in disease-relevant cells

PLoS One 8 (2013) e59436


Normal ODA defect structure (e.g. DNAI1)




Transmission electron microscopy (TEM)

showing rescue of the ciliary axoneme structure

Clin Chest Med 43 (2022) 127-140



Healthy Normal; Cilia beat at approximately 10 Hz




DNAI1; (This is a video, the cilia are not moving)


High-speed video microscopy

showing rescue of ciliary beat frequency and beat pattern

Clin Chest Med 43 (2022) 127-140



Normal



Abnormal

Mucociliary clearance (MCC)

Inhaled radio-aerosol showing whole lung mucociliary clearance


Marthin et al. 2023

Patient data anticipated Q4 '24




Pulmonary Radioaerosol Mucociliary Clearance is a sensitive assay that is likely to predict clinical benefit

Comparison in MCC in PCD patients vs. Healthy Controls



Whole lung MCC in adult PCD (n=4) vs. healthy, nonsmokers (n=12). PCD patients received 4 puffs of albuterol MDI w/ spacer at 60min and performed 30 voluntary coughs between 120-150 minutes

Absolute change in Whole Lung MCC vs. FEV1 in CF






1 Donaldson et al., 2020, 2 Correlation between change in MCC (AveClr90) and FEV₁% predicted after 4 weeks of HS treatment. Pearson R²- 0.67; p = 0.002, 3 Delta AveClr90, 4 Donaldson et al., 2018, data at 1 month and 3 months from baseline, 5 Donaldson et al., 2023, 1 month from baseline Non-Confi

Novel Selective Organ Targeting (SORT) Lipid Nanoparticle (LNP) Platform






Selective organ targeting lipid nanoparticles (SORT LNPs) deliver diverse genetic payloads beyond the liver







SORT LNPs use an **endogenous targeting mechanism of action** through adsorption of specific plasma proteins




Extra-hepatic delivery of SORT LNPs occurs via an ApoE-independent mechanism











IV SORT LNPs demonstrate differential extrahepatic selectivity




- Screened ~200 unique LNP formulations in rats via IV administration
- LNPs identified with high lung expression relative to established benchmark LNPs
- Validated hits in rats via intracellular expression of an orthogonal protein product (DNAI1-HA)



Direct and Persistent in vivo Gene Editing of Mouse Lung Epithelial Cells




Durable in vivo gene editing in Ai14 mouse lung with LNP-Cas9*



Days after injection

- First direct evidence of genetic edit of lung epithelial cells, including stem cells, following IV SORT LNP administration.
- High editing efficiency *in vivo*, with persistence for nearly 2 years.

Only LNP platform that provides **FTO** with a **large and chemically diverse library** of LNPs **without** requirement for **stacked-licenses**





Corporate Overview

July 2024

